{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:30:28Z","timestamp":1790400628698,"version":"4.1.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00535-016-1227-8","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T10:46:24Z","timestamp":1466592384000},"page":"751-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":218,"title":["Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015"],"prefix":"10.1007","volume":"51","author":[{"given":"Katsuhiko","family":"Iwakiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Habu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Hoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyuki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooru","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"issue":"Suppl 2","key":"1227_CR1","first-page":"S1","volume":"44","author":"J Dent","year":"1998","unstructured":"Dent J, Brun J, Fendric AM, et al. An evidence-based appraisal of reflux disease management the Genval Workshop Report. Gut. 1998;44(Suppl 2):S1\u201316.","journal-title":"Gut"},{"key":"1227_CR2","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR3","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/archinte.1995.00430200044008","volume":"155","author":"KR DeVault","year":"1995","unstructured":"DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med. 1995;155:2165\u201373.","journal-title":"Arch Intern Med"},{"key":"1227_CR4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1572-0241.1999.1123_a.x","volume":"94","author":"KR DeVault","year":"1999","unstructured":"DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434\u201342.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","volume":"100","author":"KR DeVault","year":"2005","unstructured":"DeVault KR, Castell DO. American College of Gastroenterology Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190\u2013200.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1440-1746.2004.03419.x","volume":"19","author":"KM Fock","year":"2004","unstructured":"Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004;19:357\u201367.","journal-title":"J Gastroenterol Hepatol"},{"issue":"50","key":"1227_CR7","first-page":"4","volume":"2015","author":"M Yoshida","year":"2014","unstructured":"Yoshida M, Kinoshita Y, Watanabe M, JSGE Clinical Practice Guidelines. standards, methods, and process of developing the guidelines. J Gastroenterol. 2014;2015(50):4\u201310.","journal-title":"J Gastroenterol"},{"key":"1227_CR8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1440-1746.2011.06707.x","volume":"26","author":"A Mizuta","year":"2011","unstructured":"Mizuta A, Adachi K, Furuta K, et al. Different sex-related influences of eating habits on the prevalence of reflux esophagitis in Japanese. J Gastroenterol Hepatol. 2011;26:1060\u20134.","journal-title":"J Gastroenterol Hepatol"},{"key":"1227_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000235919","volume":"81","author":"H Yasuhara","year":"2010","unstructured":"Yasuhara H, Miyake Y, Toyokawa T, et al. Large waist circumference is a risk factor for reflux esophagitis in Japanese males. Digestion. 2010;81:181\u20137.","journal-title":"Digestion"},{"key":"1227_CR10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s10620-011-1679-x","volume":"56","author":"T Murao","year":"2011","unstructured":"Murao T, Sakurai K, Mihara S, et al. Lifestyle change influences on GERD in Japan: a study of participants in a health examination program. Dig Dis Sci. 2011;56:2857\u201364.","journal-title":"Dig Dis Sci"},{"key":"1227_CR11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00535-008-2235-0","volume":"43","author":"M Kusano","year":"2008","unstructured":"Kusano M, Kouzu T, Kawano T, et al. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008;43:833\u201341.","journal-title":"J Gastroenterol"},{"key":"1227_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"Y Fujiwara","year":"2009","unstructured":"Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518\u201334.","journal-title":"J Gastroenterol"},{"key":"1227_CR13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/00365520510023260","volume":"40","author":"I Mishima","year":"2005","unstructured":"Mishima I, Adachi K, Arima N, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40:1005\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s10620-008-0542-1","volume":"54","author":"K Iwakiri","year":"2009","unstructured":"Iwakiri K, Kawami N, Sano H, et al. Mechanisms of excessive esophageal acid exposure in patients with reflux esophagitis. Dig Dis Sci. 2009;54:1686\u201392.","journal-title":"Dig Dis Sci"},{"key":"1227_CR15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1440-1746.2001.02617.x","volume":"16","author":"K Adachi","year":"2001","unstructured":"Adachi K, Fujishiro H, Katsube T, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol. 2001;16:1191\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"1227_CR16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","volume":"45","author":"LR Lundell","year":"1999","unstructured":"Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172\u201380.","journal-title":"Gut"},{"key":"1227_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10620-007-0038-4","volume":"53","author":"Y Hayashi","year":"2008","unstructured":"Hayashi Y, Iwakiri K, Kotoyori M, et al. Mechanisms of acid gastroesophageal reflux in the Japanese population. Dig Dis Sci. 2008;53:1\u20136.","journal-title":"Dig Dis Sci"},{"issue":"611\u20137","key":"1227_CR18","first-page":"e172","volume":"22","author":"S Kuribayashi","year":"2010","unstructured":"Kuribayashi S, Kusano M, Kawamura O, et al. Mechanism of gastroesophageal reflux in patients with obstructive sleep apnea syndrome. Neurogastroenterol Motil. 2010;22(611\u20137):e172.","journal-title":"Neurogastroenterol Motil"},{"key":"1227_CR19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1053\/gast.2000.20191","volume":"119","author":"MA Herwaarden van","year":"2000","unstructured":"van Herwaarden MA, Samsom M, Smout AJPM. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology. 2000;119:1439\u201346.","journal-title":"Gastroenterology"},{"key":"1227_CR20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0016-5085(91)80003-R","volume":"100","author":"S Sloan","year":"1991","unstructured":"Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology. 1991;100:596\u2013605.","journal-title":"Gastroenterology"},{"key":"1227_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","volume":"41","author":"R Fass","year":"2007","unstructured":"Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"1227_CR22","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1440-1746.2006.04817.x","volume":"22","author":"K Iwakiri","year":"2007","unstructured":"Iwakiri K, Hayashi Y, Kotoyori M, et al. Defective triggering of secondary peristalsis in patients with non-erosive reflux disease. J Gastroenterol Hepatol. 2007;22:2208\u201311.","journal-title":"J Gastroenterol Hepatol"},{"key":"1227_CR23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00535-009-0070-6","volume":"44","author":"K Iwakiri","year":"2009","unstructured":"Iwakiri K, Kawami N, Sano H, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol. 2009;44:708\u201312.","journal-title":"J Gastroenterol"},{"key":"1227_CR24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000309483","volume":"82","author":"K Iwakiri","year":"2010","unstructured":"Iwakiri K, Sano H, Tanaka Y, et al. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy. Digestion. 2010;82:156\u201361.","journal-title":"Digestion"},{"issue":"Suppl 1","key":"1227_CR25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2036.2004.01990.x","volume":"20","author":"H Miwa","year":"2004","unstructured":"Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(Suppl 1):112\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.mcg.0000225673.76475.9d","volume":"40","author":"A Nagahara","year":"2006","unstructured":"Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40:891\u20135.","journal-title":"J Clin Gastroenterol"},{"key":"1227_CR27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2036.2007.03584.x","volume":"27","author":"NM Thoua","year":"2008","unstructured":"Thoua NM, Khoo D, Kalantzis C, et al. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2008;27:396\u2013403.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/00365520701815074","volume":"43","author":"N Manabe","year":"2008","unstructured":"Manabe N, Haruma K, Hata J, et al. Differences in recognition of heartburn symptoms between Japanese patients with gastroesophageal reflux, physicians, nurses, and healthy lay subjects. Scand J Gastroenterol. 2008;43:398\u2013402.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/00365520701864635","volume":"43","author":"UC Ghoshal","year":"2008","unstructured":"Ghoshal UC, Chourasia D, Tripathi S, et al. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry. Scand J Gastroenterol. 2008;43:654\u201361.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00535-010-0276-7","volume":"45","author":"K Fujimoto","year":"2010","unstructured":"Fujimoto K, Hongo M. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol. 2010;45:1193\u2013200.","journal-title":"J Gastroenterol"},{"key":"1227_CR31","first-page":"6","volume":"8","author":"MB Fennerty","year":"2006","unstructured":"Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. MedGenMed. 2006;8:6.","journal-title":"MedGenMed"},{"key":"1227_CR32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888\u201391.","journal-title":"J Gastroenterol"},{"key":"1227_CR33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1365-2036.2009.04142.x","volume":"30","author":"R Jones","year":"2009","unstructured":"Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30:1030\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00365529850166149","volume":"33","author":"F Johnsson","year":"1998","unstructured":"Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998;33:15\u201320.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR35","first-page":"1997","volume":"92","author":"BE Schenk","year":"1997","unstructured":"Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92:1997\u20132000.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7326\/0003-4819-140-7-200404060-00011","volume":"140","author":"ME Numans","year":"2004","unstructured":"Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518\u201327.","journal-title":"Ann Intern Med"},{"key":"1227_CR37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2036.1990.tb00495.x","volume":"4","author":"EC Klinkenberg-Knol","year":"1990","unstructured":"Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesphageal 24-hour pH monitoring and oeosphageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther. 1990;4:485\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2036.2008.03596.x","volume":"27","author":"B Nojkov","year":"2008","unstructured":"Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of Co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27:473\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/dji024","volume":"97","author":"H Pohl","year":"2005","unstructured":"Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"1227_CR40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2036.2005.02558.x","volume":"22","author":"F Pace","year":"2005","unstructured":"Pace F, Negrini C, Wiklund I, et al. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/110241500750008565","volume":"166","author":"V Velanovich","year":"2000","unstructured":"Velanovich V. Quality of life and severity of symptoms in Gastro-oesophageal reflux disease: a clinical review. Eur J Surg. 2000;166:516\u201325.","journal-title":"Eur J Surg"},{"key":"1227_CR42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","volume":"16","author":"M Robinson","year":"2002","unstructured":"Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16:445\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR43","doi-asserted-by":"crossref","unstructured":"Bytzer P. Goals of therapy and guideline for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroentero1 2003; 98(Suppl):S31-9.","DOI":"10.1016\/S0002-9270(03)00013-3"},{"key":"1227_CR44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2036.2004.01916.x","volume":"19","author":"V Meineche-Schmidt","year":"2004","unstructured":"Meineche-Schmidt V, Hauschildt Juhl H, \u00d8stergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-esophageal reflux symptoms in primary care. Aliment Pharmacol Ther. 2004;19:907\u201315.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3111\/13696990903227739","volume":"12","author":"M Hongo","year":"2009","unstructured":"Hongo M, Kinoshita Y, Miwa H, et al. Characteristics affecting health-related quality of life (HRQOL) in Japanese patients with reflux oesophagitis and the effect of lansoprazole on HRQOL. J Med Econ. 2009;12:182\u201391.","journal-title":"J Med Econ"},{"key":"1227_CR46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2036.2008.03921.x","volume":"29","author":"M Nocon","year":"2009","unstructured":"Nocon M, Labenz J, Jaspersen D, et al. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow up results of the ProGERD study. Aliment Pharmacol Ther. 2009;29:662\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2036.2010.04336.x","volume":"32","author":"V Talwar","year":"2010","unstructured":"Talwar V, Wurm P, Bankart MJG, et al. Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease: controlled study of lansoprazole vs. placebo. Aliment Pharmacol Ther. 2010;32:191\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR48","unstructured":"Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroentero1 1997; 92(4 Suppl):30S-34S; discussion: 34S-35S."},{"issue":"Suppl","key":"1227_CR49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bpg.2004.06.011","volume":"18","author":"PH Katelaris","year":"2004","unstructured":"Katelaris PH. An evaluation of current GERD therapy: a summary and comparison of effectiveness, adverse effects and costs of drugs, surgery and endoscopic therapy. Best Prac Res Clin Gastroenterol. 2004;18(Suppl):39\u201345.","journal-title":"Best Prac Res Clin Gastroenterol"},{"key":"1227_CR50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/pmj.78.922.465","volume":"78","author":"MP Jones","year":"2002","unstructured":"Jones MP. Acid suppression in gastro-oesophageal reflux disease: why? how? How much and when? Post-grad Med J. 2002;78:465\u20138.","journal-title":"Post-grad Med J"},{"issue":"Suppl 5","key":"1227_CR51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2036.2004.02143.x","volume":"20","author":"JA Jankowski","year":"2004","unstructured":"Jankowski JA, Anderson M. Review article: management of oesophageal adenocarcinoma\u2013 control of acid bile and inflammation in intervention strategies for Barrett\u2019s oesophagus. Aliment Pharmacol Ther. 2004;20(Suppl 5):71\u201380.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archinte.166.9.965","volume":"166","author":"T Kaltenbach","year":"2006","unstructured":"Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166:965\u201371.","journal-title":"An evidence-based approach. Arch Intern Med."},{"key":"1227_CR53","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/ajg.2009.77","volume":"104","author":"Y Kinoshita","year":"2009","unstructured":"Kinoshita Y, Ashida K, Miwa H, et al. The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor. Am J Gastroenterol. 2009;104:1106\u201311.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR54","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.159.7.649","volume":"159","author":"RH Hunt","year":"1999","unstructured":"Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159:649\u201357.","journal-title":"Arch Intern Med"},{"key":"1227_CR55","unstructured":"Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophgitis (review). Cochrane Database Syst Rev 2007; (2):CD003244."},{"issue":"Suppl 1","key":"1227_CR56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.1995.tb00777.x","volume":"9","author":"RH Hunt","year":"1995","unstructured":"Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1995;9(Suppl 1):3\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR57","doi-asserted-by":"crossref","unstructured":"van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (review). Cochrane Database Syst Rev 2006; (3):CD002095.","DOI":"10.1002\/14651858.CD002095.pub3"},{"issue":"Suppl. 1","key":"1227_CR58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0953-0673.2004.01835.x","volume":"19","author":"J Tack","year":"2004","unstructured":"Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum of a unique acid-related disorder? Aliment Pharmacol Ther. 2004;19(Suppl. 1):28\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"1227_CR59","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0002-9270(03)00009-1","volume":"98","author":"R Fass","year":"2003","unstructured":"Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(Suppl):S2\u20137.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF01307584","volume":"37","author":"DO Castell","year":"1992","unstructured":"Castell DO, Dalton CB, Becker D, et al. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid. Dig Dis Sci. 1992;37:589\u201393.","journal-title":"Dig Dis Sci"},{"key":"1227_CR61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/BF02343223","volume":"146","author":"JP Buts","year":"1987","unstructured":"Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24\u00a0h continuous pH monitoring in infants and children. Eur J Pediatr. 1987;146:156\u20138.","journal-title":"Eur J Pediatr"},{"key":"1227_CR62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2036.2011.04678.x","volume":"34","author":"MA Kwiatek","year":"2011","unstructured":"Kwiatek MA, Roman S, Fareeduddin A, et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial \u2018acid pocket\u2019 in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34:59\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2036.2006.03135.x","volume":"25","author":"T Tran","year":"2007","unstructured":"Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25:143\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR64","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2036.2000.00759.x","volume":"14","author":"KG Mandel","year":"2000","unstructured":"Mandel KG, Daggy BP, Brodie DA, et al. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14:669\u201390.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2036.1998.00283.x","volume":"12","author":"T Poynard","year":"1998","unstructured":"Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther. 1998;12:159\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-230X-12-18","volume":"12","author":"D Pouchain","year":"2012","unstructured":"Pouchain D, Bigard MA, Liard F, et al. Gaviscon \u00ae vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012;12:18\u201326.","journal-title":"BMC Gastroenterol."},{"key":"1227_CR67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF01308159","volume":"28","author":"DY Graham","year":"1983","unstructured":"Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28:559\u201363.","journal-title":"Dig Dis Sci"},{"key":"1227_CR68","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00365528509089680","volume":"20","author":"O Grove","year":"1985","unstructured":"Grove O, Bekker C, Jeppe-Hansen MG, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985;20:457\u201361.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/00365528909093066","volume":"24","author":"R Weberg","year":"1989","unstructured":"Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24:401\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR70","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798\u2013810.","journal-title":"Gastroenterology"},{"key":"1227_CR71","first-page":"1072","volume":"49","author":"Y Habu","year":"2000","unstructured":"Habu Y, Kiyota K, Asada M, et al. Omeprazole versus famotidine for the treatment of lower-grade reflux esophagitis: a randomized controlled trial in Japan. Shin-yaku to Rinsho. 2000;49:1072\u20138 (in Japanese).","journal-title":"Shin-yaku to Rinsho"},{"key":"1227_CR72","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00535-005-1704-y","volume":"40","author":"Y Habu","year":"2005","unstructured":"Habu Y, Maeda K, Kusuda T, et al. \u201cProton-pump inhibitor-first\u201d strategy versus \u201cstep-up\u201d strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol. 2005;40:1029\u201335.","journal-title":"J Gastroenterol"},{"key":"1227_CR73","first-page":"1881","volume":"58","author":"Y Habu","year":"2000","unstructured":"Habu Y, Oyasu K, Wakamatsu T, et al. Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist. Nihon Rinsho. 2000;58:1881\u20135 (in Japanese).","journal-title":"Nihon Rinsho."},{"key":"1227_CR74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clinthera.2010.03.020","volume":"32","author":"S Haag","year":"2010","unstructured":"Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20\u00a0mg once daily with nizatidine or ranitidine 150\u00a0mg twice daily. Clin Ther. 2010;32:678\u201390.","journal-title":"Clin Ther"},{"key":"1227_CR75","doi-asserted-by":"crossref","unstructured":"Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013; 5:CD002095.","DOI":"10.1002\/14651858.CD002095.pub5"},{"key":"1227_CR76","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2036.2010.04517.x","volume":"33","author":"H Miwa","year":"2011","unstructured":"Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease\u2014a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR77","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1046\/j.1365-2036.2003.01562.x","volume":"17","author":"RM Klok","year":"2003","unstructured":"Klok RM, Postma MJ, van Hout BA, et al. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003;17:1237\u201345.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR78","first-page":"234","volume":"110","author":"Y Kinoshita","year":"2013","unstructured":"Kinoshita Y, Miwa H, Kasugai K. Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-. Nihon Shokakibyo Gakkai Zasshi. 2013;110:234\u201342 (in Japanese).","journal-title":"Nihon Shokakibyo Gakkai Zasshi."},{"key":"1227_CR79","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2036.1996.56198000.x","volume":"10","author":"AS Mee","year":"1996","unstructured":"Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther. 1996;10:757\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR80","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1067\/mcp.2002.127637","volume":"72","author":"T Furuta","year":"2002","unstructured":"Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"1227_CR81","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.2003.01539.x","volume":"17","author":"M Kawamura","year":"2003","unstructured":"Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003;17:965\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR82","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00042737-200108000-00006","volume":"13","author":"CJ Rensburg von","year":"2001","unstructured":"von Rensburg CJ, Bardhan KD. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2001;13:909\u201314.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1227_CR83","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00535-011-0488-5","volume":"47","author":"K Tominaga","year":"2012","unstructured":"Tominaga K, Iwakiri R, Fujimoto K, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47:284\u201392.","journal-title":"J Gastroenterol"},{"key":"1227_CR84","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ajg.2012.19","volume":"107","author":"Y Kinoshita","year":"2012","unstructured":"Kinoshita Y, Hongo M, Mitsui S, et al. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107:522\u201330.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR85","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004836-200403000-00020","volume":"38","author":"K Adachi","year":"2004","unstructured":"Adachi K, Komazawa Y, Mihara T, et al. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. J Clin Gastroenterol. 2004;38:297\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"1227_CR86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/gast.2002.31876","volume":"122","author":"WK Fackler","year":"2002","unstructured":"Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625\u201332.","journal-title":"Gastroenterology"},{"key":"1227_CR87","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1046\/j.1365-2036.2000.00882.x","volume":"14","author":"R Fass","year":"2000","unstructured":"Fass R, Murthy U, Hayden CW, et al. Omeprazole 40\u00a0mg once a day is equally effective as lansoprazole 30\u00a0mg twice a day in symptom control of patients with gastro- oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000;14:1595\u2013603.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR88","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00535-011-0446-2","volume":"46","author":"T Furuta","year":"2011","unstructured":"Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273\u201383.","journal-title":"J Gastroenterol"},{"key":"1227_CR89","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3748\/wjg.v17.i14.1858","volume":"17","author":"M Sugimoto","year":"2011","unstructured":"Sugimoto M, Nishino M, Kodaira C, et al. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol. 2011;17:1858\u201365.","journal-title":"World J Gastroenterol"},{"key":"1227_CR90","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1440-1746.2007.05218.x","volume":"23","author":"M Miyamoto","year":"2008","unstructured":"Miyamoto M, Haruma K, Takeuchi K, et al. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23:746\u201351.","journal-title":"J Gastroenterol Hepatol"},{"key":"1227_CR91","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","volume":"52","author":"GH Koek","year":"2003","unstructured":"Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397\u2013402.","journal-title":"Gut"},{"key":"1227_CR92","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-009-0173-0","volume":"45","author":"S Futagami","year":"2010","unstructured":"Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45:413\u201321.","journal-title":"J Gastroenterol"},{"key":"1227_CR93","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2169\/internalmedicine.49.3615","volume":"49","author":"M Miyamoto","year":"2010","unstructured":"Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49:1469\u201376.","journal-title":"Intern Med"},{"key":"1227_CR94","doi-asserted-by":"crossref","unstructured":"Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 2: CD003245.","DOI":"10.1002\/14651858.CD003245.pub2"},{"key":"1227_CR95","first-page":"1504","volume":"62","author":"Y Habu","year":"2004","unstructured":"Habu Y, Yoshino T, Shio S, et al. Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist. Nihon Rinsho. 2004;62:1504\u20139 (in Japanese).","journal-title":"Nihon Rinsho"},{"key":"1227_CR96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.2005.02555.x","volume":"22","author":"A Caos","year":"2005","unstructured":"Caos A, Breiter J, Perdomo C, et al. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20\u00a0mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22:193\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR97","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00535-010-0276-7","volume":"45","author":"K Fujimoto","year":"2010","unstructured":"Fujimoto K. Hongo M; Maintenance Study Group. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol. 2010;45:1193\u2013200.","journal-title":"J Gastroenterol"},{"key":"1227_CR98","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","volume":"11","author":"R Carlsson","year":"1997","unstructured":"Carlsson R, Galmiche JP, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997;11:473\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR99","first-page":"46","volume":"36","author":"Y Habu","year":"2003","unstructured":"Habu Y, Ikeura T, Shio S, et al. A cost-effectiveness analysis for the therapeutic strategy of reflux esophagitis based on endoscopic findings. Shoukakika. 2003;36:46\u201350 (in Japanese).","journal-title":"Shoukakika"},{"key":"1227_CR100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2036.1999.00564.x","volume":"13","author":"T Lind","year":"1999","unstructured":"Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907\u201314.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR101","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","volume":"15","author":"NJ Talley","year":"2001","unstructured":"Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20\u00a0mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of \u2018on-demand\u2019 therapy for 6 months. Aliment Pharmacol Ther. 2001;15:347\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2004.01999.x","volume":"20","author":"P Bytzer","year":"2004","unstructured":"Bytzer P, Blum A, De Herdt D, et al. Six-month trial of on-demand rabeprazole 10\u00a0mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2036.2008.03877.x","volume":"29","author":"P Juul-Hansen","year":"2009","unstructured":"Juul-Hansen P, Rydning A. On-demand requirements of patients with endoscopy-negative gastro-oesophageal reflux disease: H2-blocker vs. proton pump inhibitor. Aliment Pharmacol Ther. 2009;29:207\u201312.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR104","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2036.2005.02637.x","volume":"22","author":"MA Bigard","year":"2005","unstructured":"Bigard MA, Genestin E. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. Aliment Pharmacol Ther. 2005;22:635\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","volume":"20","author":"HH Tsai","year":"2004","unstructured":"Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20\u00a0mg on-demand is more acceptable to patients than continuous lansoprazole 15\u00a0mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther. 2004;20:657\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR106","first-page":"286","volume":"40","author":"Y Habu","year":"2005","unstructured":"Habu Y, Maeda K, Kusuda T, et al. A cost-effectiveness analysis for the therapeutic strategy of non-erosive reflux disease. Shokakika. 2005;40:286\u201390 (in Japanese).","journal-title":"Shokakika"},{"key":"1227_CR107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2008.00452.x","volume":"12","author":"T Szucs","year":"2009","unstructured":"Szucs T, Thalmann C, Michetti P, et al. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland. Value Health. 2009;12:273\u201381.","journal-title":"Value Health"},{"key":"1227_CR108","first-page":"67","volume":"56","author":"B Tepes","year":"2009","unstructured":"Tepes B, Stabuc B, Kocijancic B, et al. Maintenance therapy of gastroesophageal reflux disease patients with omeprazole. Hepatogastroenterology. 2009;56:67\u201374.","journal-title":"Hepatogastroenterology"},{"key":"1227_CR109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000236025","volume":"81","author":"AW Velden van der","year":"2010","unstructured":"van der Velden AW, de Wit NJ, Quartero AO, et al. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion. 2010;81:43\u201352.","journal-title":"Digestion"},{"key":"1227_CR110","first-page":"163","volume":"31","author":"N Sato","year":"2003","unstructured":"Sato N, Ohkusa T, Mitachi Y, et al. Assessment of patient satisfaction after one-month administration of omeprazole tablets for repeated recurrence of reflux esophagitis: a patient satisfaction survey using self-reporting questionnaire. Yakuri to Chiryo. 2003;31:163\u201375 (in Japanese).","journal-title":"Yakuri to Chiryo"},{"key":"1227_CR111","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1155\/2012\/235476","volume":"26","author":"SJ Zanten van","year":"2012","unstructured":"van Zanten SJ, Henderson C, Hughes N. Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review. Can J Gastroenterol. 2012;26:196\u2013204.","journal-title":"Can J Gastroenterol"},{"key":"1227_CR112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1018881617038","volume":"43","author":"Y Haga","year":"1998","unstructured":"Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43:253\u20137.","journal-title":"Dig Dis Sci"},{"key":"1227_CR113","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","volume":"36","author":"CS Jianu","year":"2012","unstructured":"Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36:644\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR114","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2036.2009.03998.x","volume":"29","author":"JW Freston","year":"2009","unstructured":"Freston JW, Hisada M, Peura DA, et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Phamacol Ther. 2009;29:1249\u201360.","journal-title":"Aliment Phamacol Ther"},{"key":"1227_CR115","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2009.05.021","volume":"7","author":"L Lundell","year":"2009","unstructured":"Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes 12\u00a0years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7:1292\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1227_CR116","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/gut.53.1.12","volume":"53","author":"EJ Kuipers","year":"2004","unstructured":"Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004;53:12\u201320.","journal-title":"Gut"},{"key":"1227_CR117","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/ajg.2009.172","volume":"104","author":"H-B Yang","year":"2009","unstructured":"Yang H-B, Sheu B-S, Wang S-T, et al. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. Am J Gastroenterol. 2009;104:1642\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR118","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00002018-200831080-00004","volume":"31","author":"H Tamim","year":"2008","unstructured":"Tamim H, Duranceau A, Qi Chen L, et al. Association between use of acid-suppressive drugs and risk of gastric cancer: a nested case-control study. Drug Saf. 2008;31:675\u201384.","journal-title":"Drug Saf"},{"key":"1227_CR119","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","volume":"100","author":"AH Poulsen","year":"2009","unstructured":"Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503\u20137.","journal-title":"Br J Cancer"},{"key":"1227_CR120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1053\/j.gastro.2007.06.014","volume":"133","author":"DJ Robertson","year":"2007","unstructured":"Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755\u201360.","journal-title":"Gastroenterology"},{"key":"1227_CR121","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1572-0241.2007.01665.x","volume":"103","author":"EM Soest van","year":"2008","unstructured":"van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966\u201373.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR122","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","volume":"102","author":"J Leonard","year":"2007","unstructured":"Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047\u201356.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR123","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cgh.2011.09.030","volume":"10","author":"A Deshpande","year":"2012","unstructured":"Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:225\u201333.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1227_CR124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1586\/ecp.12.20","volume":"5","author":"C Giuliano","year":"2012","unstructured":"Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta- analysis. Expert Rev Clin Pharmacol. 2012;5:337\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1227_CR125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","volume":"106","author":"S Ngamruengphong","year":"2011","unstructured":"Ngamruengphong S, Leontiadis GI, Radhi S. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209\u201319.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR126","unstructured":"Hayashi T, Ogino H, Hirai S, et al. A case of collageneous colitis showing improvement by discontinuation of lansoprazole was reported with a review of 182 cases in Japan. Nihon Shokaki Naishikyo Gakkai Koushin-etsu Hokuriku Shibu Kikannshi, 27:30\u20136, 53 (in Japanese)."},{"key":"1227_CR127","first-page":"101","volume":"17","author":"K Abe","year":"2012","unstructured":"Abe K, Kurahara K, Sakai Y, et al. Clinical features of collageneous colitis. Clinics in Digestive Tract. 2012;17:101\u20136 (in Japanese).","journal-title":"Clinics in Digestive Tract"},{"key":"1227_CR128","first-page":"1357","volume":"20","author":"K Hotta","year":"2008","unstructured":"Hotta K, Oyama T, Miyata Y, et al. Incidence of microscopic colitis in patients who presented with chronic diarrhea: outcome of retrospective study in Japan of colonoscopic random biopsies. Shoukaki Naishikyo. 2008;20:1357\u201361 (in Japanese).","journal-title":"Shoukaki Naishikyo"},{"key":"1227_CR129","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2036.2010.04453.x","volume":"32","author":"D Keszthelyi","year":"2010","unstructured":"Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32:1124\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1227_CR130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989\u201397.","journal-title":"Lancet"},{"key":"1227_CR131","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"T Simon","year":"2011","unstructured":"Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123:474\u201382.","journal-title":"Circulation"},{"key":"1227_CR132","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909\u201317.","journal-title":"N Engl J Med"},{"key":"1227_CR133","first-page":"856","volume":"124","author":"YH Ren","year":"2011","unstructured":"Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl). 2011;124:856\u201361.","journal-title":"Chin Med J (Engl)"},{"key":"1227_CR134","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2010.11.056","volume":"140","author":"P-I Hsu","year":"2011","unstructured":"Hsu P-I, Lai K-H, Liu C-P, et al. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011;140:791\u20138.","journal-title":"Gastroenterology"},{"key":"1227_CR135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijcard.2012.03.085","volume":"167","author":"CS Kwok","year":"2013","unstructured":"Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167:965\u201374.","journal-title":"Int J Cardiol"},{"key":"1227_CR136","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","volume":"12","author":"T Ito","year":"2010","unstructured":"Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448\u201357.","journal-title":"Curr Gastroenterol Rep"},{"key":"1227_CR137","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s10620-009-0993-z","volume":"54","author":"MR Ally","year":"2009","unstructured":"Ally MR, Veerappan GR, Maydonovitch CL, et al. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. Dig Dis Sci. 2009;54:2617\u201322.","journal-title":"Dig Dis Sci"},{"key":"1227_CR138","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00535-010-0207-7","volume":"45","author":"M Hongo","year":"2010","unstructured":"Hongo M, Fujimoto K, Yabana T, et al. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45:618\u201324.","journal-title":"J Gastroenterol"},{"key":"1227_CR139","first-page":"1328","volume":"45","author":"HJ Stein","year":"1998","unstructured":"Stein HJ, Feussner H, Siewert JR. Antireflux surgery: a current comparison of open and laparoscopic approaches. Hepatogastroenterology. 1998;45:1328\u201337.","journal-title":"Hepatogastroenterology"},{"key":"1227_CR140","first-page":"146","volume":"11","author":"S Ozawa","year":"2005","unstructured":"Ozawa S, Yoshida M, Kumai K, et al. New endoscopic treatments for gastroesophageal reflux disease. Ann Thorac Cardiovasc Surg. 2005;11:146\u201353.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"1227_CR141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1553350606296389","volume":"13","author":"M Anvari","year":"2006","unstructured":"Anvari M, Allen C, Marshall J, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov. 2006;13:238\u201349.","journal-title":"Surg Innov"},{"key":"1227_CR142","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MEG.0b013e3282f47995","volume":"20","author":"RS Gillies","year":"2008","unstructured":"Gillies RS, Stratford JM, Booth MI, et al. Does laparoscopic antireflux surgery improve quality of life in patients whose gastro-oesophageal reflux disease is well controlled with medical therapy? Eur J Gastroenterol Hepatol. 2008;20:430\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1227_CR143","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/ajg.2009.228","volume":"104","author":"JA Broeders","year":"2009","unstructured":"Broeders JA, Draaisma WA, de Vries DR, et al. The preoperative reflux pattern as prognostic indicator for long-term outcome after Nissen fundoplication. Am J Gastroenterol. 2009;104:1922\u201330.","journal-title":"Am J Gastroenterol"},{"key":"1227_CR144","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10388-009-0220-1","volume":"7","author":"N Omura","year":"2010","unstructured":"Omura N, Kashiwagi H, Yano F, et al. Postoperative recurrence factors of GERD in the elderly after laparoscopic fundoplication. Esophagus. 2010;7:31\u20135.","journal-title":"Esophagus"},{"key":"1227_CR145","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.285.18.2331","volume":"285","author":"SJ Spechler","year":"2001","unstructured":"Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331\u20133.","journal-title":"JAMA"},{"key":"1227_CR146","first-page":"2264","volume":"337","author":"AM Grant","year":"2008","unstructured":"Grant AM, Wileman SM, Ramsay CR, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:2264\u201371.","journal-title":"BMJ"},{"key":"1227_CR147","first-page":"1","volume":"3","author":"SM Wileman","year":"2010","unstructured":"Wileman SM, McCann S, Grant AM, et al. Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database of Systematic Reviews. 2010;3:1\u201338.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"1227_CR148","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3109\/00365521.2012.683041","volume":"47","author":"R Johannessen","year":"2012","unstructured":"Johannessen R, Petersen H, Olberg P, et al. Airway symptom and sleeping difficulties in operated and non-operated patients with gastroesophageal reflux disease. Scan J Gastroenterol. 2012;47:762\u20139.","journal-title":"Scan J Gastroenterol"},{"key":"1227_CR149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11605-011-1739-8","volume":"16","author":"G Zaninotto","year":"2012","unstructured":"Zaninotto G, Parante P, Salvador R, et al. Long-term follow-up of Barrett\u2019s epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg. 2012;16:7\u201315.","journal-title":"J Gastrointest Surg"},{"key":"1227_CR150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1553350611409593","volume":"18","author":"A Brillantino","year":"2011","unstructured":"Brillantino A, Schettino M, Torelli F, et al. Laparoscopic Nissen-Rossetti fundoplication is a safe and effective treatment for both acid and bile gastroesophageal reflux in patients poorly responsive to proton pump inhibitor. Surg innovation. 2011;18:387\u201393.","journal-title":"Surg innovation"},{"key":"1227_CR151","first-page":"1","volume":"12","author":"A Grant","year":"2008","unstructured":"Grant A, Wileman S, Ramsay C, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease\u2014a UK collaborative study. The REFLUX trial. Health Technol Assess. 2008;12:1\u201398.","journal-title":"The REFLUX trial. Health Technol Assess"},{"key":"1227_CR152","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jval.2010.09.004","volume":"14","author":"R Goeree","year":"2011","unstructured":"Goeree R, Hopkins R, Marshall JK, et al. Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: a 3-year prospective randomized controlled trial and economic evaluation. Value in Health. 2011;14:263\u201373.","journal-title":"Value in Health"},{"key":"1227_CR153","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/00365529950172943","volume":"34","author":"ME Luostarinen","year":"1999","unstructured":"Luostarinen ME, Isolauri JO. Surgical experience improves the long-term results of Nissen fundoplication. Scand J Gastroenterol. 1999;34:117\u201320.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR154","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/003655202753416768","volume":"37","author":"R Sandbu","year":"2002","unstructured":"Sandbu R, Khamis H, Gustavsson S, et al. Laparoscopic antireflux surgery in routine hospital care. Scand J Gastroenterol. 2002;37:132\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"1227_CR155","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00464-003-9198-2","volume":"18","author":"S Contini","year":"2004","unstructured":"Contini S, Scarpignato C. Does the learning phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication? Surg Endosc. 2004;18:266\u201371.","journal-title":"Surg Endosc"},{"key":"1227_CR156","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00464-001-9223-2","volume":"16","author":"S Contini","year":"2002","unstructured":"Contini S, Bertile A, Nervi G, et al. Quality of life for patients with gastroesophageal reflux disease 2\u00a0years after laparoscopic fundoplication: evaluation of the results obtained during the initial evidence. Surg Endosc. 2002;16:1555\u201360.","journal-title":"Surg Endosc"},{"key":"1227_CR157","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.amjsurg.2005.02.002","volume":"189","author":"H Hwang","year":"2005","unstructured":"Hwang H, Turner LJ, Blair NP. Examining the learning curve of laparoscopic fundoplication at an urban community hospital. Am J Surg. 2005;189:522\u20136.","journal-title":"Am J Surg"},{"key":"1227_CR158","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/PL00021300","volume":"14","author":"G Zaninotto","year":"2000","unstructured":"Zaninotto G, Molena D, Ancona E. A prospective multicenter study of laparoscopic treatment of gastroesophageal reflux disease in Italy: type of surgery, conversions, complications, and early results. Surg Endosc. 2000;14:282\u20138.","journal-title":"Surg Endosc"},{"key":"1227_CR159","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00464-006-0013-8","volume":"21","author":"BS Hakanson","year":"2007","unstructured":"Hakanson BS, Thor KB, Thorell A, et al. Open vs laparoscopic partial posterior fundoplication. Surg Endosc. 2007;21:289\u201398.","journal-title":"Surg Endosc"},{"key":"1227_CR160","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0039-6060(99)70136-4","volume":"126","author":"V Velanovich","year":"1999","unstructured":"Velanovich V. Comparison of symptomatic and quality of life outcomes of laparoscopic versus open antireflux surgery. Surgery. 1999;126:782\u20139.","journal-title":"Surgery"},{"key":"1227_CR161","first-page":"328","volume":"97","author":"RT Juan","year":"2005","unstructured":"Juan RT, S\u00e1nchez TT, Mart\u00ednez EM, et al. Surgery for gastroesophageal reflux disease: a comparative study between the open and laparoscopic approaches. Rev Esp Enferm Dis. 2005;97:328\u201337.","journal-title":"Rev Esp Enferm Dis"},{"key":"1227_CR162","first-page":"539","volume":"168","author":"T Franz\u00e9n","year":"2002","unstructured":"Franz\u00e9n T, Anderberg B, Grahn LT, et al. Prospective evaluation of laparoscopic and open 360* fundoplication in mild and severe gastro-oesophageal reflux disease. Eur J Surg. 2002;168:539\u201354.","journal-title":"Eur J Surg"},{"key":"1227_CR163","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1445-2197.2010.05481.x","volume":"81","author":"G Tan","year":"2011","unstructured":"Tan G, Yang Z, Wang Z. Meta-analysis of laparoscopic total (Nissen) versus posterior (Toupet) fundoplication for gastro-oesophageal reflux disease based on randomized clinical trials. ANZ J Surg. 2011;81:246\u201352.","journal-title":"ANZ J Surg"},{"key":"1227_CR164","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/bjs.7174","volume":"97","author":"JA Broeders","year":"2010","unstructured":"Broeders JA, Mauritz FA, Ahmed Ali U, et al. Systematic review and meta-analysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal reflux disease. Br J Surg. 2010;97:1318\u201330.","journal-title":"Br J Surg"},{"key":"1227_CR165","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00464-008-9872-5","volume":"22","author":"J Hafez","year":"2008","unstructured":"Hafez J, Wrba F, Lenglinger J, et al. Fundoplication for gastroesophageal reflux and factors associated with outcome 6\u201310\u00a0years after the operation: multivariate analysis of prognostic factors using the propensity score. Surg Endosc. 2008;22:1763\u20138.","journal-title":"Surg Endosc"},{"key":"1227_CR166","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-009-0064-4","volume":"44","author":"S Ozawa","year":"2009","unstructured":"Ozawa S, Kumai K, Higuchi K, et al. Short-term outcome of endoluminal gastroplication for the treatment of GERD: the first multicenter trial. J Gastroenterol. 2009;44:675\u201384.","journal-title":"J Gastroenterol"},{"key":"1227_CR167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0016-5107(05)00336-6","volume":"61","author":"YK Chen","year":"2005","unstructured":"Chen YK, Raijman I, Ben-Menachem T, et al. Long-term outcomes of endoluminal gastroplication: a US multicenter trial. Gastrointest Endosc. 2005;61:659\u201367.","journal-title":"Gastrointest Endosc"},{"key":"1227_CR168","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2007-995515","volume":"40","author":"D Renteln von","year":"2008","unstructured":"von Renteln D, Brey U, Riecken B, et al. Endoscopic full-thickness placation (Plicator) with two serially placed implants improves esophagitis and reduced PPI use and esophageal acid exposure. Endoscopy. 2008;40:173\u20138.","journal-title":"Endoscopy"},{"key":"1227_CR169","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11605-009-1027-z","volume":"14","author":"CJ Filipi","year":"2010","unstructured":"Filipi CJ, Stadlhuber RJ. Initial experience with new intraluminal device for GERD Barrett esophagus and obesity. J Gastrointest Surg. 2010;14:121\u20136.","journal-title":"J Gastrointest Surg"},{"key":"1227_CR170","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00464-011-2050-1","volume":"26","author":"PA Testoni","year":"2012","unstructured":"Testoni PA, Vailati C, Testoni S, et al. Transoral incisioness fundoplication (TIF 2.0) EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. Surg Endosc. 2012;26:1425\u201335.","journal-title":"Surg Endosc"},{"key":"1227_CR171","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3748\/wjg.v17.i39.4429","volume":"17","author":"H Liu","year":"2011","unstructured":"Liu H, Zhang J, Li J, et al. Improvement of clinical parameters in patients with gastroesophageal reflux disease after radiofrequency energy delivery. World J Gastroenterol. 2011;17:4429\u201333.","journal-title":"World J Gastroenterol"},{"key":"1227_CR172","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1052-5157(02)00115-0","volume":"13","author":"H Luis","year":"2003","unstructured":"Luis H, Devi\u00e8re J. Endoscopic implantation of enteryx for the treatment of gastroesophageal reflux disease: technique, pre-clinical and clinical experience. Gastrointest Endosc Clin N Am. 2003;13:191\u2013200.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"1227_CR173","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1052-5157(02)00112-5","volume":"13","author":"P Fockens","year":"2003","unstructured":"Fockens P. Gatekeeper reflux repair system: technique, pre-clinical, and clinical experience. Gastrointest Endosc Clin N Am. 2003;13:179\u201389.","journal-title":"Gastrointest Endosc Clin N Am"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1227-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1227-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T20:01:51Z","timestamp":1718654511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1227-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":173,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1227-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,21]]}}}